Sales of antiarrhythmic medicines in Sweden have shown a stable pattern from 2014 to 2021, maintaining a consistent sales value of 0.2 units. However, in 2022, sales dropped by 50% to 0.1 units and remained steady through 2023. Future forecasts predict no change from this 0.1 unit level through to 2028. Over the last five years, the compound annual growth rate (CAGR) has been negative at -12.94%, reflecting the significant decline in 2022. While stability is expected in the upcoming years, the market remains cautious.
Future trends to watch for:
- Potential medical advancements in antiarrhythmic treatments.
- Healthcare policies in Sweden that may impact drug sales.
- Changes in the prevalence of arrhythmic conditions.
